Ignite Creation Date:
2024-05-05 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00369356
Status:
COMPLETED
Last Update Posted:
2013-01-23
First Post:
2006-08-24
Brief Title:
Cortisone or Drug Eluting Stents DES as Compared to Bare Metal Stents BMS to EliminAte Restenosis
Sponsor:
Universita di Verona
Organization:
Universita di Verona
Study Overview
Official Title:
Clinical and Angiographic Outcome of Patients Treated With Bare Metal Stent BMS Implantation Compared With Drug Eluting Stents or BMS Plus Systemic Prednisone Therapy A Randomized Multicentre Study
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The possibility of using the new drug eluting stents DES technology has significantly changed the mid-term outcome of percutaneous coronary interventions PCI in terms of reduced recurrence of angina The way interventionalists accomplish their work is changing accordingly with a strong trend to a wider use of DES and a consequent perceived patients clinical benefit
Evidences supporting the superiority of DES in reducing ischemic recurrence after PCI compared to traditional stents BMS are available from randomized studies A recent meta-analyses underlines that
DES are superior to BMS in reducing clinical recurrence of ischemia DES and BMS offer identical results in terms of death and infarction Rapamycin and paclitaxel DES offer similar results
The aim of our study is to perform a multicenter randomized study to assess the clinical efficacy and safety of the oral prednisone therapy after PCI as a possible systemic alternative to currently available BMS and DES Furthermore the study aims at analyzing the clinical outcome of the commercially available DES in the context of an independent research and a cost-benefit comparison with BMS and oral steroids
Evidences supporting the superiority of DES in reducing ischemic recurrence after PCI compared to traditional stents BMS are available from randomized studies A recent meta-analyses underlines that
DES are superior to BMS in reducing clinical recurrence of ischemia DES and BMS offer identical results in terms of death and infarction Rapamycin and paclitaxel DES offer similar results
The aim of our study is to perform a multicenter randomized study to assess the clinical efficacy and safety of the oral prednisone therapy after PCI as a possible systemic alternative to currently available BMS and DES Furthermore the study aims at analyzing the clinical outcome of the commercially available DES in the context of an independent research and a cost-benefit comparison with BMS and oral steroids
Detailed Description:
Design of the study
It is very important to underline that this is a spontaneous study ie not receiving sponsorship from pharmaceutical industries stent manufacturers or any other financial source This independence from economic interests would contribute to exclude conflicts of interest that may bias the results of the study that is aimed at testing the applicability and the clinical efficacy of this therapy Furthermore the assessment of the DES in public hospitals and beyond the spectrum of the industry-supported studies may offer interesting results of the real life use of these devices
One of the purposes of the study is a cost-effectiveness analysis Centers participating in the study should therefore perform PCI according to their common practice with no interference in their decision-making process or technical approach to PCI because of the inclusion of the patients into a randomized study this is aimed at obtaining an as real as possible situation of the daily practice Being an spontaneous research neither a fee will be provided for the enrollment of patients nor free stents will be given
The allocation of patients into a BMS or DES treatment will be decided by randomization and the stents implanted will be selected according to the operators preference
The study will include three different groups of patients
Control group receiving BMS
DES group receiving DES
Prednisone group receiving BMS and oral prednisone
Principal objective of the study is the comparison of the primary endpoint obtained in a control group of patients treated with BMS versus two alternative study groups
DES
BMS and oral prednisone All assuming a similar adjunctive conventional medical treatment
Secondary endpoint of the study are
cost-effectiveness analysis This will be calculated considering all patients enrolled in the study and analyzed after one year of the treatment The analysis will take into account the procedural cost of the PCI material the cost of the medical treatment in the first year of follow-up and the number of event-free days at follow-up The cost-efficacy analysis will be obtained from the ratio between the cost of the event-free day of follow-up and the possibility of MACE considered in the primary endpoint of the study
comparison of the angiographic results This will be calculated in all patients enrolled
It is very important to underline that this is a spontaneous study ie not receiving sponsorship from pharmaceutical industries stent manufacturers or any other financial source This independence from economic interests would contribute to exclude conflicts of interest that may bias the results of the study that is aimed at testing the applicability and the clinical efficacy of this therapy Furthermore the assessment of the DES in public hospitals and beyond the spectrum of the industry-supported studies may offer interesting results of the real life use of these devices
One of the purposes of the study is a cost-effectiveness analysis Centers participating in the study should therefore perform PCI according to their common practice with no interference in their decision-making process or technical approach to PCI because of the inclusion of the patients into a randomized study this is aimed at obtaining an as real as possible situation of the daily practice Being an spontaneous research neither a fee will be provided for the enrollment of patients nor free stents will be given
The allocation of patients into a BMS or DES treatment will be decided by randomization and the stents implanted will be selected according to the operators preference
The study will include three different groups of patients
Control group receiving BMS
DES group receiving DES
Prednisone group receiving BMS and oral prednisone
Principal objective of the study is the comparison of the primary endpoint obtained in a control group of patients treated with BMS versus two alternative study groups
DES
BMS and oral prednisone All assuming a similar adjunctive conventional medical treatment
Secondary endpoint of the study are
cost-effectiveness analysis This will be calculated considering all patients enrolled in the study and analyzed after one year of the treatment The analysis will take into account the procedural cost of the PCI material the cost of the medical treatment in the first year of follow-up and the number of event-free days at follow-up The cost-efficacy analysis will be obtained from the ratio between the cost of the event-free day of follow-up and the possibility of MACE considered in the primary endpoint of the study
comparison of the angiographic results This will be calculated in all patients enrolled
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None